Re-186 HEDP treatment in breast cancer patients with bone metastases.
Koutsikos
John
J
Leondi
Anastasia
A
D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000008:administration & dosage; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C064573:rhenium-186(tin)etidronate; D012968:Etidronic Acid